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The aim of this study was to determine if cultured
porcine vascular smooth muscle cells (pSMCs) that had
been maintained on different extracellular matrix pro-
teins had an alteration in their expression of insulin-like
growth factor binding protein-5 (IGFBP-5) and their re-
sponsiveness to insulin-like growth factor-I (IGF-I).
When pSMCs were plated on fibronectin, they synthe-
sized 6.0 6 1.2-fold more IGFBP-5 than did cells main-
tained on laminin and type IV collagen. IGF-I increased
IGFBP-5 gene expression 3-fold in the cells plated on
fibronectin. The addition of an RGD peptide and
echistatin to pSMC cultures that had been plated on
fibronectin inhibited IGFBP-5 mRNA expression. The
addition of an antibody against a2b1 integrin partially
reversed the inhibitory effects of laminin and type IV
collagen on IGFBP-5 expression. Cells maintained on
fibronectin had a 5.0 6 1.1-fold greater DNA synthesis
response to IGF-I compared with those maintained on
laminin/type IV collagen, and echistatin significantly
inhibited the DNA synthesis response of the fibronectin-
maintained cells to IGF-I. The anti-a2b1 antibody par-
tially reversed the inhibitory effect of laminin and type
IV collagen on IGF-I-stimulated DNA synthesis. The ad-
dition of IGFBP-5 to cultures plated on laminin and type
IV collagen significantly increased their response to
IGF-I. Atherosclerotic plaques from pig aorta contained
abundant fibronectin and had increased IGFBP-5
mRNA (4.5 6 1.5-fold) compared with tissue from the
normal vessel wall that had a low fibronectin content.
These results indicate that fibronectin, laminin, and
type IV collagen have major effects on IGFBP-5 expres-
sion and on IGF-I-stimulated pSMC responses and that
these effects are mediated by their respective integrins.
Vascular smooth muscle cells (SMCs)1 in the media of nor-
mal blood vessels are surrounded by a basement membrane
that contains type IV collagen and laminin and maintain a
differentiated, contractile state characterized by abundant
myofilaments and expression of contractile protein isoforms
such as a-actin (1). They are quiescent, and the proliferative
index is low (1). In contrast, SMCs in the neointima seem to
have dedifferentiated. This dedifferentiation includes a
marked structural reorganization of the cells, with loss of myo-
filaments and the formation of an extensive rough endoplasmic
reticulum and large Golgi complex (2–4). Their abundance of
smooth muscle a-actin decreases, whereas the expression of
nonmuscle b- and g-actin increases (2–4). They synthesize
increased amounts of fibronectin and deposit it into their ex-
tracellular matrix (ECM). This is termed the synthetic pheno-
type, and these cells have acquired the ability to proliferate,
migrate, and synthesize ECM in response to stimulation by
growth factors and cytokines (5). Additionally, cells in the
synthetic phenotype constitutively synthesize peptide growth
factors, and they have the ability to replicate in the absence of
exogenously added mitogens (1).
Extracellular matrix has been shown to play an important
role in the modulation of the SMC phenotype in culture (6).
Aortic SMCs assume the synthetic phenotype when they are
cultured on a fibronectin substratum and will proliferate in
response to stimulation by appropriate growth factors. In con-
trast, if the cells are cultured on laminin and type IV collagen,
they will remain in the contractile phenotype. These ECM
proteins function by binding to their integrin receptors on the
cell surface. Cultured SMCs express the a5b1 and aVb3 inte-
grins, which bind fibronectin, and the a2b1 integrin, which
binds to laminin and several forms of collagen (7).
The growth and differentiation of SMCs are modulated by a
number of peptide growth factors, including the IGFs. SMCs in
culture have been shown to synthesize IGF-I, and IGF-I stim-
ulates SMC proliferation in an autocrine fashion (8–10). In
vivo, IGF-I mRNA and immunoreactive IGF-I are detected in
atherosclerotic lesions that develop after injury (11), and the
increase in IGF-I mRNA and immunoreactive peptide after
balloon denudation injury precedes an associated increase in
SMC proliferation (12, 13). IGF-I has also been shown to stim-
ulate SMC migration (14), and this response is mediated by the
IGF-I receptors but also requires ligand occupancy of the aVb3
integrin. This ligand occupancy of integrins may play a role in
controlling IGF-I responsiveness.
The bioactivities of IGFs are modulated by a group of spe-
cific, high affinity IGF binding proteins (IGFBPs) (15). Previ-
ous studies have shown that porcine aortic SMCs secrete
IGFBP-2, -4, and -5 (16, 17) and that IGFBP-5 can modulate
IGF-I-stimulated cell proliferation and migration (18). Because
modulation of their phenotypic state alters pSMC responses to
peptide growth factors, we determined the ability of specific
EMC components to regulate IGFBP-5 expression and the re-
sponsiveness of these cells to IGF-I.
EXPERIMENTAL PROCEDURES
Materials—Human fibronectin, type IV collagen, laminin, and
echistatin were purchased from Sigma. The peptides GRGESP and
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GRGDSP were purchased from Telios Pharmaceuticals Inc. (San Diego,
CA). Recombinant human IGF-I was obtained from Bachem Inc. (Tor-
rance, CA). Polyvinylidene difluoride filters were supplied by Millipore
Corp. Autoradiographic film was purchased from Eastman Kodak
(Rochester, NY). Fetal bovine serum, Dulbecco’s modified Eagle’s me-
dium, and penicillin-streptomycin were purchased from Life Technolo-
gies, Inc. P1E6, a monoclonal antibody against the a2b1 integrin, was a
gift from Dr. Leslie Parise (Department of Pharmacology at UNC-
Chapel Hill). Trypsin was obtained from Boehringer Mannheim.
[3H]Thymidine was purchased from ICN Biomedicals, Inc. (Costa Mesa,
CA). [32P]dCTP was purchased from Amersham Corp. Polyclonal anti-
sera against IGFBP-2 and -5 were prepared as described previously (19,
20, 39). A monoclonal antibody that was specific for smooth muscle
a-actin and rhodamine-labeled phalloidin were purchased from Sigma.
Maintenance of Porcine Aortic Smooth Muscle Cells (pSMCs) in Cul-
ture—pSMCs were obtained from thoracic aortas of pigs using a previ-
ously described method (21). They were maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 4.5/liter glucose, 100
units/ml penicillin, 100 mg/ml streptomycin, 4 mM glutamine, and 10%
fetal bovine serum (complete medium) in 10-cm tissue culture plates
(Falcon 3001). The cells were used between passages 2 and 5. To culture
the cells on specific ECM proteins, the cells were detached with trypsin/
EDTA, trypsin was neutralized with 10% fetal bovine serum, and the
cells were rinsed twice with serum-free DMEM and suspended in the
same medium. They were then plated on tissue culture plates or glass
coverslips that had been exposed to specific ECM proteins at a density
of 2 3 104 cell/cm2. The surfaces of culture dishes or glass coverslips
were precoated with fibronectin (1 mg/cm2) or type IV collagen (2 mg/
cm2) plus laminin (1 mg/cm2) by incubating the mixture at room tem-
perature for 4–5 h as recommended by the manufacturer. The liquid
was then aspirated, and the dishes were rinsed twice with PBS and
maintained in DMEM-H/0.01% bovine serum albumin for 15 min before
use. To attach IGFBP-5 to matrix proteins, the plates that contained
the ECM proteins were rinsed twice with binding buffer (Eagle’s min-
imal essential medium without bicarbonate, supplemented with 20 mM
Hepes, pH 7.4, and 0.01% bovine serum albumin) and incubated over-
night at 4 °C with the same buffer and 100 ng/ml of IGFBP-5 or with
buffer alone. The wells were then rinsed twice with PBS before use. In
some experiments, the cells were incubated with an RGD peptide,
echistatin, or anti-a2b1 antibody (P1E6) at the indicated concentration
for 15 min before the cells were plated on culture dishes.
Immunocytochemistry—The cells were plated on glass coverslips pre-
coated with ECM substrates for 2 days before they were fixed in 2%
formaldehyde in PBS for 20 min and then permeabilized with 0.2%
Triton X-100 in PBS for 3 min. To determine the expression of smooth
muscle a-actin, the cells were exposed to a 1:200 dilution of a mono-
clonal antibody prepared against smooth muscle a-actin for 2 h followed
by 1:500 dilution of fluorescein isothiocyanate-labeled goat anti-mouse
IgG for 30 min. To determine the expression of total actin, the cells were
exposed to 1:500 dilution of rhodamine-labeled phalloidin. They were
rinsed with PBS, mounted in 90% glycerol with 0.1% paraphenylenedi-
amine, and then analyzed using a Nikon Labophot microscope with
epifluorescence optics.
RNA Isolation and Northern Blotting—RNA was isolated from cell
cultures by Tri-Reagent following the manufacturer’s instructions (Mo-
lecular Research Center, Inc., Cincinnati, OH) and then quantified by
measuring UV absorbance at 260 nm. To isolate RNA from pig aortas,
the tissue specimens were obtained from atherosclerotic lesions and
from normal aortic subendothelium from six pigs who had been fed a
high fat diet for 4 months (22). These are early proliferative phase
lesions that contain abundant monocytes, macrophages, and smooth
muscle cells. The lesion tissue was immediately frozen in liquid nitro-
gen and pulverized at 280 °C using pre-cooled mortar and pestle. The
pulverized tissues were then homogenized for 1 min with Polytron
homogenizer in the presence of Tri-Reagent. RNA was isolated as
described previously (17). The RNA samples were size fractionated on a
1.2% agarose/formaldehyde gel, blotted, fixed onto nylon membranes
(Biotrans, ICN Biochemical Inc.), and then hybridized with either a
[32P]dCTP-labeled human 627-base pair IGFBP-5 cDNA probe (17) or a
542-base pair IGFBP-2 cDNA probe (15). The probes were labeled to
specific activities of 200 mCi/mg by random priming (15). The relative
abundance of the radiolabeled bands was determined by PhosphorIm-
age analysis using Image Quant SF (Molecular Dynamics).
Western Immunoblotting Analysis—The pSMC cultures were rinsed
with PBS and scraped into SDS sample buffer containing 100 mM
dithiothreitol. The protein concentration of each sample was deter-
mined by the BCA protein assay (Pierce), and equal amounts of protein
(5 mg) per lane were loaded onto 12.5% SDS-polyacrylamide gels. The
separated proteins were then transferred to filters (Immobilon PSQ,
0.45-mm pore size, Millipore). The filters were exposed to a monoclonal
antibody against smooth muscle a-actin (diluted at 1:1,000 in TBS
containing 3% bovine serum albumin) for 14 h at 4 °C. The immunoblots
were developed with the enhanced chemiluminescence detection system
according to the manufacturer’s recommendation (Amersham). To de-
termine the fibronectin content in the aortic tissue specimens, the
tissue was immediately frozen in liquid nitrogen and then pulverized at
280 °C. The pulverized tissues were transferred into tubes to which
lysis buffer containing 20 mM Tris-HCl, pH 7.4, 2% Triton X-100, 10 mM
EDTA had been added. The suspension was homogenized for 1 min at
4 °C followed by centrifugation for 5 min at 12,000 3 g at 4 °C. The
protein concentration in the supernatant was measured and adjusted to
1 mg/ml by adding 2 3 Laemmli sample buffer with 0.1 M dithiothreitol.
30 mg of protein was loaded per gel lane, and the proteins in the mixture
were separated by 7.5% SDS-polyacrylamide gel electrophoresis
(PAGE) in the presence of 0.1 M dithiothreitol. The separated proteins
were transferred to Immobilon PSQ filters. Fibronectin was detected
with anti-fibronectin polyclonal antibody using a 1:1000 dilution, and
the immune complexes were detected by chemiluminescence according
to the procedure cited above.
Immunoprecipitation of IGFBPs—To analyze IGFBP synthesis and
secretion into conditioned medium, pSMC monolayers were exposed to
50 mCi/ml [35S]methionine (56 Ci/mmol) for 8 h in methionine-deficient
(1026 M) DMEM. The medium was incubated with a 1:1000 dilution of
anti-IGFBP-5 or 1:1000 dilution of anti-IGFBP-2 antisera, and the
immune complexes were precipitated with protein A-Sepharose as de-
scribed previously (17). The precipitates were analyzed by SDS-PAGE
with fluorography and autoradiography (17).
Cell Replication—To measure [3H]thymidine incorporation into por-
cine smooth muscle cells, pSMCs were plated at a density of 2 3 104/cm2
in 48-well culture plates (Costar 3548) that had been precoated with
fibronectin or type IV collagen and laminin with or without IGFBP-5, as
described previously. In some experiments, pSMCs were preincubated
with echistatin 1027 M or the P1E6 antibody at a dilution of 1:500 for 15
min before they were plated on the fibronectin or laminin plus type IV
collagen. The cultures were maintained for 24 h in serum-free DMEM
(with or without the various treatments); then, fresh DMEM (0.1 ml)
supplemented with 0.2% human platelet-poor plasma (21), 1 mCi/well
[3H]thymidine (specific activity, 35 mCi/mmol), and IGF-I (0–20 ng/ml)
were added. After 24 h, the plates were placed on ice, washed with
ice-cold phosphate-buffered saline twice, and incubated with ice-cold
5% trichloroacetic acid for 10 min. The trichloroacetic acid precipitates
were solubilized by adding 0.1 ml of 1% SDS, 0.1 N NaOH overnight,
and radioactivity was quantified using a Beckman scintillation counter
using ScintiSafe Econo 2 (Fisher Scientific) as a scintillant. In some
experiments, the cell number was determined in a particle data counter
(model ZBI, Coulter Electronics, Hialeah, FL). For these experiments,
the cells were plated at a density of 2 3 104 cells/cm2 in 24-well plates
(Costar 3424). After 24 h, the treatments were added, and the incuba-
tion continued for 36 h. The cells were detached with 0.2% trypsin, and
the cell number was determined.
RESULTS
Expression of Smooth Muscle (SM) a-Actin—SM a-actin was
used as a marker for SMC differentiation. Indirect immunoflu-
orescence microscopy showed that the percentage of cells with
microfilament bundles that stained intensely for smooth mus-
cle a-actin was greater when the cultures were plated on lami-
nin plus type IV collagen compared with cultures plated on
fibronectin (Fig. 1A). Immunoblotting analysis with a mono-
clonal antibody against smooth muscle a-actin was also used to
examine the effect of the different substrata on the level of
smooth muscle a-actin expression. A single band of 42 kDa was
detected. A direct comparison by immunoblotting showed that
pSMCs cultured on fibronectin contain 4.7-fold less smooth
muscle a-actin than the cells plated on laminin plus type IV
collagen (Fig. 1B). Thus, the cells that were plated on laminin/
type IV collagen maintained this important property of differ-
entiated pSMC. In contrast, the expression of total actin was
not decreased in pSMCs plated on fibronectin, as demonstrated
using rhodamine-labeled phalloidin (Fig. 1C).
Extracellular Matrix Proteins Regulate IGFBP-5 Synthesis
and Secretion—Cultures that were plated on fibronectin or
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laminin/type IV collagen had significant differences in the
amount of IGFBP-5 that was synthesized and secreted. As
shown in Fig. 2A, media obtained from the cells grown on
fibronectin had a 1.7-fold 6 0.3 (p , 0.05) increase in intact
IGFBP-5 compared with cultures maintained on plastic. More
important, the amount of IGFBP-5 was 4.0 6 1.0-fold (p , 0.01)
greater than the cells that were plated on laminin/type IV
collagen. In contrast, the synthesis of IGFBP-2 was unchanged
when cells that were cultured using these conditions were
compared (Fig. 2B).
To determine if the change of IGFBP-5 synthesis was accom-
panied by a corresponding change in mRNA, total RNA was
isolated from the cells cultured on laminin plus type IV colla-
gen or fibronectin and analyzed by Northern blotting. Com-
pared with cultures maintained on plastic, plating on fibronec-
tin increased IGFBP-5 mRNA levels by 1.5 6 0.3-fold (p , 0.05)
(Fig. 3). In contrast, in the cultures plated on laminin and type
IV collagen, the IGFBP-5 mRNA abundance was decreased by
85 6 6% (p , 0.01) compared with control cultures. The ex-
pression of IGFBP-2 mRNA showed no significant changes
(Fig. 3).
Influence of ECM on the Ability of IGF-I to Regulate IGFBP-5
mRNA Abundance—As IGFBP-5 gene expression has been
shown to be stimulated by IGF-I (17), we examined whether
maintaining the cultures on different ECM proteins would
alter this cellular response. As shown in Fig. 4, IGF-I increased
IGFBP-5 mRNA abundance in the pSMCs that had been plated
on either fibronectin or laminin plus type IV collagen. Although
cells maintained in laminin/type IV collagen responded to
IGF-I with an increase in IGFBP-5 expression (6.1 6 1.0 to
41 6 5.0, arbitrary units p , 0.01), the absolute level of
IGFBP-5 mRNA was substantially below that detected in cul-
tures that had been maintained on fibronectin (54 6 4.0 to
140 6 15, arbitrary units p , 0.01).
Cell Replication Assays of pSMCs Cultured on Different ECM
Substrata—pSMCs cultured on different substrata were also
analyzed for their ability to synthesize DNA in response to
IGF-I. The results showed that the response to IGF-I was
significantly greater (560 6 84% compared with 112 6 12%,
p , 0.01) for cells plated on fibronectin compared with cells
plated on laminin plus type IV collagen (Fig. 5). These data are
consistent with the responses in Fig. 4 showing that cells
plated on type IV collagen retain some capacity to respond to
IGF-I, but the absolute level that can be attained is decreased
significantly. The addition of IGFBP-5 to cultures that were
plated on laminin and type IV collagen resulted in marked
potentiation of the cellular response to IGF-I. In contrast, the
addition of IGFBP-5 to cultures plated on fibronectin did not
alter the cellular response to IGF-I significantly.
The Effect of Different ECM Proteins Is Mediated by Their
Respective Integrins—As pSMCs have been reported to express
a5b1, avb3, and a2b1 integrins, we examined whether blocking
ligand binding to these integrins would influence IGFBP-5
expression. Following a 30-min exposure to synthetic peptides
or to anti-integrin antibodies, the cells were plated on fibronec-
tin or laminin/type IV collagen dishes. The adherence of pSMC
to the substratum was unaffected by preincubating with the
FIG. 1. A, immunohistochemical staining of smooth muscle a-actin in
pSMCs cultured on fibronectin (FN) or laminin plus type IV collagen
(L/C) for 48 h. The cells were exposed to monoclonal anti-SM a-actin for
2 h followed by fluorescein isothiocyanate-labeled goat anti-mouse IgG.
SM a-actin was demonstrated by indirect immunofluorescence micros-
copy. B, immunoblot analysis of smooth muscle a-actin. pSMCs were
maintained on fibronectin or laminin plus type IV collagen. Cell lysates
were prepared by solubilizing the cells with 2 3 Laemmli sample buffer,
analyzed by SDS-PAGE, transferred to Immobilon-P, and immuno-
blotted using a 1:1000 dilution of a monoclonal antibody that had been
raised against SM a-actin. SM a-actin was detected by chemilumines-
cence. C, immunohistochemical staining of total actin in pSMCs cul-
tured on fibronectin or laminin plus type IV collagen for 48 h. The cells
were exposed to rhodamine-labeled phalloidin for 30 min. Total actin
was demonstrated by indirect immunofluorescence microscopy.
FIG. 2. Effects of ECM substratum on the synthesis of IGFBP-5
(A) and IGFBP-2 (B). SMCs were cultured on plastic dishes (lanes 1
and 4) on fibronectin (lanes 2 and 5) or laminin plus type IV collagen
(lanes 3 and 6) for 48 h (lanes 1–3) and 96 h (lanes 4–6). During the last
8 h of incubation, the cells were exposed to methionine-free medium
containing 50 mCi of [35S]methionine and 50 mg/ml heparin (added to
inhibit IGFBP-5 proteolysis). Culture media were collected and immu-
noprecipitated using antiserum against IGFBP-5 (A) or IGFBP-2 (B).
The immunoprecipitated proteins were analyzed by SDS-PAGE with
autoradiography. Upper panels, autoradiographs; lower panels, Phos-
phorImage analyses. This experiment was repeated three times with
similar results.
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these reagents at the given concentrations. After a 24-h incu-
bation, IGFBP-5 mRNA abundance was quantified. The syn-
thetic RGD peptide that binds a5b1 and echistatin blocked the
fibronectin-induced change in IGFBP-5 expression (Fig. 6). A
control RGE peptide had no effect. The inhibition of IGFBP-5
expression that was induced by laminin and type IV collagen
was partially reversed by the antibody against a2b1 integrin.
These data indicate that binding of these matrix proteins to
their respective integrins is an important step in their ability to
modulate IGFBP-5 expression. To determine if these integrins
were also involved in modulating the DNA synthesis response
to IGF-I, a similar experiment was conducted using [3H]thymi-
dine incorporation as an index of IGF-I action. As shown in Fig.
7, exposure of pSMC plated on fibronectin to echistatin atten-
uated the cellular DNA synthesis response to IGF-I. In con-
trast, the P1E6 antibody partially reversed the inhibitory effect
of ligand occupancy of a2b1 on IGF-I-stimulated replication. To
determine if altering ligand occupancy of these integrins would
alter the cellular growth response to IGF-I, cell number was
determined using a similar experimental design. Quiescent
pSMC cultures that were plated on fibronectin increased their
final cell number by 61 6 7% in response to 20 ng/ml of IGF-I.
The addition of echistatin (1027 M) decreased this response to
32 6 4%. The cells plated on laminin/type IV collagen increased
11 6 2.1%, and those that were exposed to the P1E6 antibody
increased 18 6 2.1%.
Atherosclerotic Lesions Contain Abundant Fibronectin and
Have Greater IGFBP-5 mRNA Expression Compared with Nor-
mal Aorta—To determine if the SMCs in lesions express more
IGFBP-5 than cells in the normal arterial wall, atherosclerotic
FIG. 3. Effects of ECM substratum on the steady-state levels of
IGFBP-5 and IGFBP-2 mRNA. A, total RNA was isolated from SMCs
that had been maintained on plastic dishes (lanes 1 and 4), on fibronec-
tin (lanes 2 and 5), or on laminin plus type IV collagen (lanes 3 and 6)
for 48 (lanes 1–3) or 96 h (lanes 4–6). Total RNA was isolated and
subjected to Northern blotting. RNAs were detected with specific cDNA
probes for human IGFBP-5 and -2. Upper panel, autoradiography of
IGFBP-5 and -2 mRNAs; middle panel, 28 S and 18 S RNA ethidium
bromide staining; lower panels, PhosphorImage analyses. This experi-
ment was repeated three times with similar results.
FIG. 4. IGF-I regulates the mRNA expression of IGFBP-5 in
pSMCs cultured on fibronectin (lanes 1–3) or laminin plus type
IV collagen (lanes 4–6). pSMCs were plated on these ECM proteins
and maintained for 24 h; then, IGF-I was added, and the incubation was
continued for another 24 h. Total RNA was isolated from the cells and
subjected to Northern blotting using the cDNA probe for human
IGFBP-5. Lanes 1 and 4, no IGF-I; lanes 2 and 5, IGF-I (50 ng/ml); lanes
3 and 6, IGF-I (100 ng/ml). Upper panel, autoradiograph of IGFBP-5
mRNA; middle panel, autoradiograph of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA; lower panel, PhosphorImage analysis
of IGFBP-5 mRNA. Three experiments were conducted with similar
results.
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lesions that were diet induced were extracted, and their RNA
was analyzed by Northern blotting. The results showed that
lesions contain 4.5 6 1.5-fold (p , 0.05) (n 5 4 separate ani-
mals) more IGFBP-5 mRNA compared with normal subendo-
thelial tissue. A representative experiment is shown in Fig. 8A.
The fibronectin content in these tissue specimens was also
determined. The results show that a 5.9-fold greater amount of
fibronectin was detected in the lesion tissue compared with
normal aorta (Fig. 8B).
DISCUSSION
In normal blood vessels, SMCs are attached to a basement
membrane that contains type IV collagen and laminin. Within
the arterial wall, most SMCs are maintained in a quiescent
state and express contractile protein isoforms. However, in
response to vascular injury, SMCs alter their phenotype and
are stimulated to proliferate and migrate. This phenotypic
transition from the contractile to the synthetic state is accom-
panied by enhanced expression of specific matrix proteins such
as fibronectin (9). The phenotypic transition can be modulated
in vitro by changing the composition of ECM substratum (6).
Aortic SMCs have been reported to convert to the synthetic
phenotype when cultured on a fibronectin substratum, and, if
maintained on fibronectin, they will proliferate if they are also
exposed to appropriate growth factors. In contrast, if the cells
are cultured on laminin plus type IV collagen, early passage
(e.g. ,p5) cells can be maintained in a nonproliferative state for
1 week (6). This was confirmed in our study by showing abun-
dant expression of smooth muscle a-actin and an increased
number of microfilament bundles that stained for a-actin. In
contrast, cells that were plated and maintained on fibronectin
had much lower a-actin content. Based on these results, we
believe that the in vitro modulation of the pSMC phenotype
was similar to that previously reported by others (6).
A major finding in the present study is that, compared with
cells cultured on laminin and type IV collagen, pSMCs cultured
on fibronectin synthesize and release more IGFBP-5. The in-
crease in IGFBP-5 synthesis is associated with increased
IGFBP-5 mRNA expression. The effect becomes manifest be-
tween the 2nd and 4th days after changing the ECM substra-
tum. The effect is specific for IGFBP-5 as IGFBP-2 protein and
mRNA levels were unaltered by the ECM proteins. This sug-
gests that expression of this gene may be an important compo-
nent of phenotype transition. Because IGFBP-5 has been
shown to potentiate the cellular growth-promoting effect of
IGF-I (23), this may be relevant to the observation noted by
several groups that synthetic phenotype cells are more respon-
sive to growth factors (9, 24–26). This conclusion is strength-
ened by our observation that the addition of IGFBP-5 to cul-
tures plated on laminin/type IV collagen enhanced their DNA
synthesis response to IGF-I, suggesting that the enhanced ex-
pression of IGFBP-5 in the fibronectin-exposed cultures may
FIG. 5. [3H]Thymidine incorporation responses to IGF-I of
pSMC plated on fibronectin or laminin plus type IV collagen.
pSMCs were plated and incubated for 24 h and then exposed to [3H]thy-
midine (1.0 mCi/well) and IGF-I at varying concentrations another 24 h.
Purified IGFBP-5 was either omitted from the assay or preincubated
with the substrata prior to plating the cells. The amount of [3H]thymi-
dine incorporated into the cells was measured by scintillation counting.
ƒ, cells plated on fibronectin; E, cells plated on laminin and type IV
collagen; ‚, cells plated on fibronectin preincubated with IGFBP-5; M,
cells plated on laminin and type IV collagen preincubated with
IGFBP-5. The results were expressed as percent of increase over that of
the cells plated on laminin and type IV collagen and incubated with
DMEM plus 0.2% platelet-poor plasma only.
FIG. 6. Effects of integrin-blocking peptides or antibodies on
IGFBP-5 mRNA expression. pSMCs were preincubated with no
treatment (lane 1), a control RGE peptide 1027 M (lane 2), RGD peptide
1027 M (lane 3), or echistatin 1027 M (lane 4) for 30 min and then plated
on fibronectin. pSMCs were incubated with no treatment (lane 5), 1:500
dilution of mouse IgG (lane 6), or 1:500 dilution of the anti-a2b1 anti-
body (lane 7) before plating on laminin plus type IV collagen. After 24 h
of incubation, the RNA was isolated from the cells and analyzed by
Northern blotting using the cDNA probe for human IGFBP-5. Upper
panel, autoradiograph; middle panel, ethidium bromide staining for 28
S and 18 S RNA; lower panel, PhosphorImage analysis.
Changes in Substratum Alters SMC Response to IGF-I8998
be an important component of this enhanced replication re-
sponse to IGF-I.
These changes were also reflected in the IGFBP-5 synthesis
response to IGF-I. We had previously shown that IGF-I induced
a 6-fold increase in IGFBP-5 mRNA (17); therefore, we ana-
lyzed the responses of pSMC that expressed each phenotype.
Although pSMC plated on fibronectin had a greater increase in
IGFBP-5 expression in response to IGF-I, cultures maintained
in the nonproliferative phenotype still showed some IGF-I re-
sponsiveness. There are two possible interpretations of this
result. First, fibronectin is acting to directly stimulate basal
(non-IGF-I dependent) IGFBP-5 expression and to enhance the
response to IGF-I. This conclusion is supported by our data
showing that peptide antagonists of ligand binding to aVb3 and
a5b1 can inhibit IGFBP-5 expression. Second, it is also possible
that a low percentage of cells have not been maintained in the
nonproliferative phenotype and, therefore, have acquired IGF-I
responsiveness. In either case, it seems that the synthetic
phenotype cells are more responsive to IGF-I. In addition to
modulating the IGFBP-5 synthesis response to IGF-I, plating
pSMC on different substrata modulated the DNA synthesis
response. This effect also seemed to be ECM protein-mediated
as cells that were plated on laminin/type IV collagen had a
reduced DNA synthesis response to IGF-I compared with the
response of cells plated on fibronectin.
To test the hypothesis that the effects of these ECM mole-
cules were mediated by their respective integrins, pSMCs were
incubated with an antibody or peptides that bind to and block
integrin ligand occupancy. The adherence of pSMCs to matrix-
coated plates was unaffected by preincubating the cells with
either RGD peptide or the antibody at the indicated concentra-
tions. These results indicate that the effect of fibronectin on
IGFBP-5 expression is mediated by a5b1 and aVb3 integrins, as
both the RGD peptide and echistatin, a disintegrin that has
been shown to block fibronectin binding to aVb3 integrin, in-
hibited the induction of IGFBP-5 by fibronectin. Because we
have previously shown that vitronectin binding to aVb3 is re-
quired for pSMC to migrate in response to IGF-I and because
echistatin also blocked the IGFBP-5 response to IGF-I, it is
likely that aVb3 occupancy by fibronectin is also augmenting
this response. In contrast to fibronectin, exposure to type IV
collagen/laminin resulted in maintenance of IGFBP-5 expres-
sion at a low level. When occupancy of the a2b1 integrin was
blocked with the P1E6 antibody, this inhibition of IGFBP-5
expression could be partially reversed. This strongly suggests
that a2b1 integrin ligand occupancy is acting to inhibit
IGFBP-5 expression. Additionally, the effects of these ECM
proteins on IGF-I-stimulated DNA synthesis seem to be inte-
grin mediated as blocking binding to a2b1 or aVb3 partially
reversed the effects of these ligands on IGF-I-stimulated rep-
lication. Taken together, these results support the conclusion
that the effects of the ECM proteins used in this study are
integrin mediated and that integrin ligand occupancy modu-
lates IGF-I responsiveness. Therefore, the capacity of this
growth factor to stimulate pSMC replication is directly related
to the context in which the growth factor signal is presented to
its cognate receptor.
IGFs exert multiple effects on target cells that are mediated
by the IGF-I receptor on the cell surface. IGF-I has been shown
to stimulate proliferation as well as migration of pSMC (14). In
addition to the direct influences on the cells, IGF-I exposure is
also required for the full activity of several other growth factors
or cytokines. IGF-I has been shown to enhance the effects of
platelet-derived growth factor (27), thrombin (28), and angio-
tensin II (29) on cultured SMCs. Selective inhibition of IGF-I
binding to its receptor with anti-IGF-I antibody results in
marked reduction in the mitogenic response to thrombin (28)
and angiotensin II (29). In vivo, IGF-I mRNA and immunore-
active IGF-I are detected in intimal lesions that develop in
humans (11). IGF-I mRNA and immunoreactive IGF-I levels
both increase severalfold after balloon denudation injury in
rats, and these increases are temporally preceded by an in-
crease in SMC proliferation (12, 13). Thus, IGF-I may be im-
portant for SMC proliferation and migration in vivo and may
play an important role in the development of atherosclerotic
lesions.
Our findings suggest that variables such as enhanced bind-
ing of fibronectin to aVb3 or increased binding of type IV colla-
FIG. 7. [3H]Thymidine incorporation responses to IGF-I of
pSMC cultured on fibronectin or laminin plus type IV collagen
and exposed to echistatin or P1E6 antibody. pSMCs were plated
on the two substrata, incubated for 24 h, and then exposed to [3H]thy-
midine (1.0 mCi/well) and IGF-I at varying concentrations for another
24 h. Treatments included the following: ƒ, cells plated on fibronectin;
‚, cells plated on fibronectin in the presence of 1027 M echistatin; M,
cells plated on laminin and type IV collagen in the presence of P1E6; E,
cells plated on laminin and type IV collagen. The results were expressed
as percent of increase over that of the cells plated on laminin and type
IV collagen and incubated with DMEM plus 0.2% platelet-poor plasma
only. The results represent the mean 6 S.E. of three separate
experiments.
FIG. 8. Fibronectin content (A) and IGFBP-5 mRNA abun-
dance (B) in cellular extracts obtained from atherosclerotic
lesion and normal vessel wall of porcine aorta. A, proteins were
extracted from tissue lysates, and fibronectin was detected by immu-
noblotting as described under “Experimental Procedures.” B, total RNA
was isolated from a representative atherosclerotic lesion and normal
vessel wall (from which the endothelial and advential cells had been
removed) and analyzed by Northern blotting. The RNA was detected
with a cDNA probe for human IGFBP-5. Lane 1, normal aorta; lane 2,
atherosclerotic lesion. RNA samples were also obtained from four sep-
arate animals and analyzed as stated above. The results were not
different from the representation example that is shown.
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gen to a2b1 may also modulate responsiveness of pSMC to other
growth factors. Recent studies have shown that ligand occu-
pancy of the aVb3 integrin functions to regulate growth factor
actions. Platelet-derived growth factor (30) and IGF-I (14) have
a diminished capacity to stimulate cell migration if ligand
occupancy of this integrin is attenuated. Similarly blocking
integrin or growth factor receptor-associated signaling path-
ways, such as induction of phosphatidylinositol-3 kinase and
inositol phosphate-3 formation, results in inhibition of migra-
tion (30). The mechanistic explanations that have been pro-
posed to explain these observations include coactivation of sig-
nal transduction elements by growth factor tyrosine kinase
receptors and integrins such as insulin receptor substrate-1
(31) or calmodulin-II kinase (32, 33) and, in the case of fibro-
blast growth factor, direct activation of the receptor kinase
activity by integrin occupancy (34). Our findings suggest that
the aVb3 occupancy is activating IGF-I signaling, resulting in
not only enhanced migration but also in enhanced replication.
In contrast, no studies have been reported to date that blocking
ligand occupancy of a2b1 will enhance growth factor actions. In
the case of platelet-derived growth factor, occupancy of this
integrin was stated to enhance the SMC migration response
(35). Therefore, further studies that are directed toward eluci-
dating the mechanism by which a2b1 occupancy is inhibiting
IGF-I actions are warranted.
IGF bioactivities are modified by a family of six high affinity
IGFBPs. Among them, IGFBP-5 has the unique property of
adhering tightly to ECM (23). When associated with ECM, the
affinity of IGFBP-5 is lowered 8-fold. This affinity shift results
in a more favorable equilibrium between IGF-I bound to ECM-
associated IGFBP-5 and to the IGF-I receptor, and this is
associated with an enhanced cellular DNA synthesis response
to IGF-I. Additionally, the amount of ECM-associated IGFBP-5
has been shown to be related to the degree of enhancement of
the cellular growth response (23). This hypothesis was con-
firmed by our results showing that the addition of IGFBP-5 to
cultures that were plated on laminin and type IV collagen
significantly increased the cellular response to IGF-I. There-
fore, factors such as the induction of IGFBP-5 synthesis by
fibronectin could result in further enhancement of the cellular
responses to IGF-I. Similarly, an increase in the affinity of aVb3
for its ligands, which occurs following IGF-I binding to its
receptor (14), may contribute to this response.
These observations may have some relevance to the develop-
ment of atherosclerotic lesions in vivo. This study demon-
strated that atherosclerotic lesions contain more IGFBP-5
mRNA compared with comparable amounts of normal vessel
wall. Although several cell types exist in atherosclerotic
plaques, SMCs are the predominant cell type (5). Similarly, as
the SMCs within lesions have assumed the synthetic pheno-
type and because fibronectin is much more abundant, it is
possible that the increase that we observed in IGFBP-5 mRNA
content in lesions reflects the differences that we observed in
pSMC cultures in vitro and that this increase could be related
to lesion enlargement. Because the aVb3 integrin is not ex-
pressed in normal vessel wall but is abundant in atheroscle-
rotic lesions (36), it is possible that this change also contributes
to enhanced IGFBP-5 expression. Furthermore, because other
ECM proteins that bind to aVb3, such as thrombospondin and
osteopontin, are abundant in lesions and have the potential to
act through aVb3 to alter the smooth muscle cell phenotype and
responsiveness (37, 38), it will be of interest to determine their
effects on IGF-I and IGFBP-5 actions.
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